Skip to main content

Axcella Health, Inc. (AXLA)

NASDAQ: AXLA · IEX Real-Time Price · USD
3.23 -0.01 (-0.31%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap123.31M
Revenue (ttm)n/a
Net Income (ttm)-58.75M
Shares Out38.18M
EPS (ttm)-1.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume64,578
Open3.21
Previous Close3.24
Day's Range3.10 - 3.31
52-Week Range2.98 - 6.84
Beta1.40
AnalystsBuy
Price Target15.13 (+368.4%)
Est. Earnings DateNov 11, 2021

About AXLA

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in J...

IndustryBiotechnology
IPO DateMay 9, 2019
Employees59
Stock ExchangeNASDAQ
Ticker SymbolAXLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Axcella Health stock is "Buy." The 12-month stock price forecast is 15.13, which is an increase of 368.42% from the latest price.

Price Target
$15.13
(368.42% upside)
Analyst Consensus: Buy

News

Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials

Image Provided By Pixabay The American Journal of Gastroenterology recently published findings from a clinical study of AXA1125, a groundbreaking potential treatment for nonalcoholic steatohepatitis (NA...

1 week ago - Benzinga

Axcella Announces Upcoming Investor Conference Presentation

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

1 week ago - Business Wire

Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Sub...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabol...

1 month ago - Business Wire

Axcella Reports Second Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

1 month ago - Business Wire

Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

1 month ago - Business Wire

Blazing Biotechs Highlight Stocks Trading Under $10 With Massive Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:ARCOJAGXNMTRLTRX
2 months ago - 24/7 Wall Street

Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

2 months ago - Business Wire

Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday

Looking for biotech penny stocks to watch before Monday? Check these 3 out The post Best Biotech Penny Stocks to Buy?

Other symbols:IBIOTYME
3 months ago - PennyStocks

Positive Clinical Data About Axcella's AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Present...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

3 months ago - Business Wire

Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

4 months ago - Business Wire

Axcella Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

4 months ago - Business Wire

Axcella to Report First Quarter 2021 Financial Results on May 6, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

4 months ago - Business Wire

Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

4 months ago - Business Wire

Exclusive: Axcella Health Aims To Become The Standard Of Care

Axcella Health Inc (NASDAQ: AXLA) is a clinical-stage biotechnology company focused on endogenous metabolic modulators, or EEMs, said Axcella Health CEO Bill Hinshaw Thursday on Benzinga's YouTube show ...

5 months ago - Benzinga

Axcella Announces AXA1125's IND Clearance for the Treatment of NASH

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

5 months ago - Business Wire

Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

6 months ago - Business Wire

Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

6 months ago - Business Wire

Axcella Announces Alison D. Schecter, M.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulat...

6 months ago - Business Wire

Axcella Announces Upcoming Presentations at NASH-TAG 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

6 months ago - Business Wire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

6 months ago - PRNewsWire

Axcella to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

7 months ago - Business Wire

Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

8 months ago - Business Wire

Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

8 months ago - Business Wire

Goldman Sachs Has 4 Sizzling Biotech Stocks to Buy That Are Under $10

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:CTMXKLDOMGTA
8 months ago - 24/7 Wall Street

Axcella Announces Upcoming Investor Conference Presentation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

9 months ago - Business Wire